Fresenius Medical Care AG (FMS)

NYQ – Real vaqt narxi. Valyuta: USD

22.24

+0.48 (2.21%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand

Fresenius Medical's shares rise after Q1 earnings miss estimates as margin expansion and FME25+ savings support operating income growth.

05.05.2026

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

05.05.2026

Fresenius Medical: The Undervaluation Is Getting Clearer

Fresenius Medical Care is undervalued at a sub-10x P/E despite 7-9% AEPS growth and improved fundamentals. FMS has achieved 300-400 bps margin expansion, €800M+ in savings, and reduced leverage to 2.5x, supporting a more robust investment-grade profile. Even with flat or low growth, FMS offers 40-60% multi-year upside to a $29/share price target, justifying a 'Buy' rating.

05.05.2026

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related one-time costs mainly drove reported operating income decline of 14% and reported net income3 decrease of 22% Earnings per share2 (EPS) increased by 16%, supported by the share buyback program FY 2026 outlook confirmed BAD HOMBURG, Germany, May 5, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income growth was in line with our planned phasing," said Helen Giza, Chief Executive Officer of Fresenius Medical Care.

05.05.2026

Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

The dialysis specialist started restructuring its U.S. network by exiting 64 of up to 100 clinics.

05.05.2026

Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

Fresenius Medical Care said on Tuesday its ‌revenue fell 6% in the first quarter of 2026, weighed down by ⁠significant currency effects, mainly from the weak U.S. dollar, and recent divestitures.

09.04.2026

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

24.02.2026

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3% Reported operating income grew by 31%, reported net income3 by 82% Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback program Dividend of EUR 1.49 (+3%) planned to be proposed FY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwinds BAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025.

09.01.2026

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

The second tranche of the share buyback is expected to be executed by May 8, 2026 The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally planned BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion.

10.12.2025

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Germany , Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026.

Fresenius Medical Care AG (FMS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Fresenius Medical Care AG (FMS)

FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Fresenius Medical: The Undervaluation Is Getting Clearer

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Videolar

No Data

Press-relizlar

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Fresenius Medical: The Undervaluation Is Getting Clearer

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Videolar

No Data

Press-relizlar

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Search stocks

Fresenius Medical Care AG (FMS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Fresenius Medical Care AG (FMS)

FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Fresenius Medical: The Undervaluation Is Getting Clearer

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Videolar

No Data

Press-relizlar

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand

Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript

Fresenius Medical: The Undervaluation Is Getting Clearer

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care Posts Lower Net Profit on One-Off Costs

Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll

Why Fresenius (FMS) is a Top Value Stock for the Long-Term

Videolar

No Data

Press-relizlar

Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed

Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board